Follow
International Journal of Current Microbiology and Applied Sciences (IJCMAS)
Home Editorial Board Current Issue Special Issue Archives Indexing Submit Article
Instruction to Authors Manuscript Charges Copyright Form Model Manuscript Process Flow (Time Frame) FAQ
Reviewer Guidelines Selection of Reviewers Join our Team of Reviewers Apply as Reviewer Reviewer Login
Editorial Review Policy Embargo Policy Ethical Expectations Consent For Identifying Information Informed Consent Manuscript Withdrawal Policy Peer Review Process Plagiarism Policy Ethical Violations Appeal Policy Against Editorial Decision Advertising Policies Authorship Policy
Access Policies Authorship Publication Policy Publication Ethics Complaints Policy Confidential Information Conflicts of Interest Policy Consent for Copyrighted Material Copyright Policy Corrections and Retractions Digital Preservation Policy Research On Human And Animal Studies Open Access Policy
Publication Ethics Contact
IJCMAS is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCMAS Articles.
Index Copernicus ICI Journals Master List 2023 - IJCMAS--ICV 2023: 95.56 For more details click here
National Academy of Agricultural Sciences (NAAS) : NAAS Score: *5.38 (2020) [Effective from January 1, 2020] For more details click here

Join as a Reviewer

Login as a Reviewer

Indexed in



National Academy of Agricultural Sciences (NAAS)
NAAS Score: *5.38 (2020)
[Effective from January 1, 2020]
For more details click here
ICV 2023: 95.56
Index Copernicus ICI Journals Master List 2023 - IJCMAS--ICV 2023: 95.56
For more details click here
Announcement

See Guidelines to Authors
Current Issues
Download Publication Certificate

Original Research Articles                      Volume : 15, Issue:4, April, 2026
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : editorijcmas@gmail.com /
submit@ijcmas.com
Editor-in-chief: Dr.M.Prakash
Index Copernicus ICV 2018: 95.39
NAAS RATING 2020: 5.38
Metrics and citations

Int.J.Curr.Microbiol.App.Sci.2026.15(4): 103-108
DOI: https://doi.org/10.20546/ijcmas.2026.1504.012


Utility of Galactomannan as Biomarker in Diagnosis of Invasive Aspergillosis: Retrospective Analysis
Abhishek Velamuri*, Krishnaveni, Rafat Fathima, K. Navya and Shiva Priya Eswaran
Department of Microbiology, Krishna Institute of Medical Sciences, Secunderabad, India
*Corresponding author
Abstract:

Invasive Aspergillosis is a systemic infection of Aspergillus species which is a filamentous fungus present in the environment causing mild to severe illness. Detection of invasive aspergillosis is recognised by microscopy, conventional culture, biomarkers and by histopathology techniques. Galactomannan antigen detection is an adjunct to early diagnosis of invasive aspergillosis. A retrospective study was done from February 2023 to February 2025 among clinical samples received to microbiology laboratory at a tertiary care. The demographic data of the patients were recorded. The sensitivity and specificity of Galactomannan using FungiXpert Detection Kit on Full-Automatic Chemiluminescence Immunoassay System and its correlation with fungal culture were compared using descriptive statistics. Out of 700 clinical samples, 214 samples were positive for Galactomannan. Among 214 galactomannan positive, 184 BAL, 30 Serum samples were positive. Out of 184 bronchoalveolar lavages, Aspergillus species was isolated in 55 samples (29%) and 129 samples showed no growth (70%). Aspergilus fumigatus as the most common species isolated in 35 samples (63 %), Aspergillus flavus in 12 samples (22%), Aspergillus terreus in 4 samples (7.2 %) and Aspergillus niger in 4 samples (7.2 %). Age group >70 years showed maximum culture positives 48 (87.2%). In this study, 53 (63.6%) males and 20 (36.3%) females were positive for invasive aspergillosis. Galactomannan is a useful biomarker in the diagnosis of invasive aspergillosis.


Keywords: Invasive aspergillosis, Aspergillus, Galactomannan, Bronchoalveolar lavage, FACIS, Filamentous fungus.

References:
  1. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. The Lancetinfectious diseases. 2005 Oct 1; 5(10): 609-22.
  2. Zhou W, Li H, Zhang Y, Huang M, He Q, Li P, Zhang F, Shi Y, Su X. Diagnostic value ofgalactomannan antigen test in serum and bronchoalveolar lavage fluid samples from patients with nonneutropenic invasive pulmonary aspergillosis. Journal of clinical microbiology. 2017 Jul; 55(7): 2153-61.
  3. Tarrand JJ, Lichterfeld M, Warraich I, Luna M, Han XY, May GS, Kontoyiannis DP. Diagnosis of invasive septate mold infections: a correlation of microbiological culture and histologic or cytologicexamination. American journal of clinical pathology. 2003 Jun 1; 119(6): 854-8.
  4. Van de Sande WW, Tavakol M, Van Vianen W, Bakker-Woudenberg IA. The effects of antifungalagents to conidial and hyphal forms of Aspergillus fumigatus. Medical Mycology. 2010 Feb1; 48(1): 48-55.
  5. Nalesnik MA, Myerowitz RL, Jenkins R, Lenkey J, Herbert D. Significance of Aspergillus speciesisolated from respiratory secretions in the diagnosis of invasive pulmonary aspergillosis. Journal of Clinical Microbiology. 1980 Apr; 11(4): 370-6.
  6. Neofytos D, Railkar R, Mullane KM, et al., Correlation between circulating fungal biomarkers and clinical outcome in invasive aspergillosis. PLoS One. 2015; 10(6): e0129022.
  7. Jenks JD, Hoenigl M. Invasive aspergillosis in 2020. J Fungi (Basel). 2020; 6(2): 77.
  8. Patterson TF, Thompson GR 3rd, Denning DW, et al., Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 63(4): e1-e60.
  9. Pfeiffer CD, Miller LS, Sutton DA, et al., Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev. 2012; (1): CD007394.
  10. Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al., Diagnosis and management of Aspergillus diseases: executive summary of the 2020 ESCMID-ECMM guideline for the diagnosis and management of aspergillosis. Clin Microbiol Infect. 2021; 27 Suppl 2: 1-21.
  11. De Pauw B, Walsh TJ, Donnelly JP, et al., Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008; 46(12): 1813-1821.
  12. Fisher CE, Stevens AM, Leisenring W, et al., Serum Galactomannan Index Predicts Mortality in Hematopoietic Stem Cell Transplant Recipients With Invasive Aspergillosis. Clin Infect Dis. 2013; 57(7): 1001-1004.
  13. Marr KA, Boeckh M, Carter RA, et al., Association between galactomannan antigenemia and outcome of invasive aspergillosis in recipients of hematopoietic stem cell transplants. Clin Infect Dis. 2007; 45(7): 835-842.
  14. Hohl TM, Hohl CE, Boeckh M. Serum galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with invasive aspergillosis. Clin Infect Dis. 2013; 57(7): 1001-1004.
  15. Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, Spriet I, Verbeken E, Van Wijngaerden E. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. American journal of respiratory and critical care medicine.2008 Jan 1; 177(1): 27-34.
  16. D'Haese J, Theunissen K, Vermeulen E, Schoemans H, De Vlieger G, Lammertijn L, Meersseman P, Meersseman W, Lagrou K, Maertens J. Detection of galactomannan in bronchoalveolar lavage fluidsamples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity. Journal of clinical microbiology. 2012 Apr; 50(4): 1258-63
  17. Wattier RL, Ramirez-Avila L. Pediatric invasive aspergillosis. Journal of Fungi. 2016 Jun 13; 2(2): 19.
  18. Coordination G, Alastruey-Izquierdo A, World Health Organization. WHO Fungal Priority Pathogens List to Guide Research. Development and Public Health Action.
  19. Shadrivova O, Desyatik E, Volkova A, Popova M, Uspenskaya O, Shneyder T, Melekhina J, Bogomolova T, Ignatyeva S, Zubarovskaya L, Afanasyev B. PB2031 INVASIVE ASPERGILLOSIS IN ELDERLY ONCOHEMATOLOGICAL PATIENTS. HemaSphere. 2019 Jun 1; 3(S1): 917-8.11.
  20. Lao M, Zhang K, Zhang M, Wang Q, Li J, Su L, Ding M, He W, Gong Y. Clinical features and co-infections in invasive pulmonary aspergillosis in elderly patients. Infection and Drug Resistance. 2020 Oct 12: 3525-34.
  21. Tio SY, Chen SC, Hamilton K, Heath CH, Pradhan A, Morris AJ, Korman TM, Morrissey O, Halliday CL, Kidd S, Spelman T. Invasive aspergillosis in adult patients in Australia and New Zealand: 2017– 2020. The Lancet Regional Health–Western Pacific. 2023 Nov 1; 40.
  22. Kim A, Nicolau DP, Kuti JL. Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States. Mycoses. 2011 Sep; 54(5): e301-12.
  23. Steinbach WJ, Marr KA, Anaissie EJ, Azie N, Quan SP, Meier-Kriesche HU, Apewokin S, Horn DL. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. Journal of Infection. 2012 Nov 1; 65(5): 453-64.
  24. Lortholary O, Gangneux JP, Sitbon K, Lebeau B, De Monbrison F, Le Strat Y, Coignard B, Dromer F, Bretagne S, French Mycosis Study Group. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007). Clinical microbiology and infection. 2011 Dec 1; 17(12): 1882-9.
  25. Hsiue HC, Wu TH, Chang TC, Hsiue YC, Huang YT, Lee PI, Hsueh PR. Culture-positive invasive aspergillosis in a medical center in Taiwan, 2000–2009. European journal of clinical microbiology & infectious diseases. 2012 Jul; 31: 1319-26.
Download this article as Download

How to cite this article:

Abhishek Velamuri, Krishnaveni, Rafat Fathima, Navya K. and Shiva Priya Eswaran. 2026. Utility of Galactomannan as Biomarker in Diagnosis of Invasive Aspergillosis: Retrospective Analysis.Int.J.Curr.Microbiol.App.Sci. 15(4): 103-108. doi: https://doi.org/10.20546/ijcmas.2026.1504.012
Copyright: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike license.

Citations
Home | Terms of Use | Copyright Form 2012-2026 Copy rights reserved IJCMAS. Powered by ThinkNEXT Technologies